The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is offering advanced development support to Hologic (NSDQ:HOLX) for a molecular diagnostic test for coronavirus (COVID-19).
Marlborough, Mass.-based Hologic’s test is the first coronavirus product selected for development through ASPR’s biomedical advanced R&D authority streamlined selection process (BARDA), which is called an easy broad agency announcement (EZ-BAA), according to a news release.
Get the full story at our sister site, MassDevice.
Filed Under: Drug Discovery and Development, Infectious Disease
